



Japan Drug Forecasts to 2026

Conduct external benchmarking & market analysis with the first consensus forecasts for Japan

Our industry-leading consensus forecasts, combined with historical sales and sales by indication for the Japanese market will help you improve valuations and decisions in your region


Evaluate Japan Drug Forecasts cover over 1,300 marketed and R&D products which make up over 85% of the total Japanese market value, based on the latest MHLW reported sales.

Sizing & Valuing Markets



Combine Japanese forecasts with Worldwide, European and US historical and forecasted sales, across multiple classification options.

Valuing Products & Companies



Use standardised consensus forecasts for product and company valuations, investigating past performance, competitive landscape and more.

Competitive Intelligence



Compare product performance and map uptake trends and drivers to analyse competitors from multiple angles.

Sales by Indication



Available for the top 25+ companies, including Takeda, Astellas Pharma, Daiichi Sankyo, Roche and more.

Benchmarking Internal Forecasts



Triangulate your numbers with industry leader in consensus forecasts by comparing internal models, as well as R&D performance benchmarks.



Monitoring Industry Trends



Model future dynamics of the Japanese market and map future trends, accessing market summaries, data alerts, news and analysis.

1,300+ Products covered – >85% of total Japan market

Sales by Indication for 960+ Products





Evaluate provides trusted commercial intelligence for the pharmaceutical industry. We help our clients to refine and transform their understanding of the past, present and future of the global pharmaceutical market to drive better decisions. When you partner with Evaluate, our constantly expanding solutions and our transparent methodologies and datasets are instantly at your disposal, along with personalized, expert support.

Evaluate gives you the time and confidence to turn understanding into insight, and insight into action.

Evaluate
Omnium provides a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, delivering game-changing insight into pharma asset potential.

EvaluatePharma offers a global view of the pharmaceutical market's past, present and future performance with consensus forecasts to 2026, company financials, pipelines and deals.

EvaluateMedTech tracks, benchmarks, and forecasts global performance for the medical device and diagnostic industry with consensus forecasts to 2026, company financials and more.

Evaluate Custom Solutions improves your strategic decision-making with customized solutions and deep insights that draw on our industry expertise and trusted commercial intelligence.

Evaluate Vantage provides award-winning, thought-provoking news and insights into current and future developments in the industry, and is the only pharmaceutical news service underpinned by Evaluate's commercial intelligence.

www.evaluate.com |  [@EvaluatePharma](https://twitter.com/EvaluatePharma)  [@EvaluateVantage](https://twitter.com/EvaluateVantage)

Evaluate Headquarters

Evaluate Ltd.
11-29 Fashion Street
London E1 6PX
United Kingdom
T +44 (0)20 7377 0800

Evaluate Americas

EvaluatePharma USA Inc.
60 State Street, Suite 1910
Boston, MA 02109
USA
T +1 617 573 9450

Evaluate Asia Pacific

Evaluate Japan KK
Holland Hills Mori Tower 2F
5-11-2 Toranomom, Minato-ku
Tokyo 105-0001, Japan
T +81 (0)80 1164 4754